研究单位：[1]Allergan[2]Peking Union Medical College Hospital 233616,Beijing,China,100730[3]Tianjin Eye Hospital 233581,Tianjin,China,300020[4]Beijing Tongren Hospital, CMU 233608,Beijing,China,100730[5]The First Xiangya Hospital of Central South University /ID# 233627,Changsha Hunan,China,410008[6]The First Affiliated Hospital of Dalian Medical University /ID# 233688,Dalian,China,116011[7]Qilu Hospital of Shandong University /ID# 233605,Jinan,China,250012[8]The Eye and ENT Hospital Affiliated of Fudan Univesity /ID# 233666,Shanghai,China,200031[9]Shanghai General Hospital 233579,Shanghai,China,200080[10]Joint Shantou International Eye Center of Shantou University and The Chinese Uni 233580,Shantou,China,515041
研究目的：
This study will take place in China to evaluate the safety and efficacy of OZURDEX implant 700 μg in the treatment of macular edema due to retinal vein occlusion (RVO) in patients who have never received treatment for RVO.
